Merit Medical Acquires View Point Medical for $140 Million to Expand Breast Cancer Localization Portfolio
核心洞察
Merit Medical Systems (搜索) acquired View Point Medical (搜索) for approximately $140 million to expand its therapeutic oncology portfolio focused on breast and soft tissue tumor localization.
The acquisition adds the FDA-cleared OneMark Detection Imaging System (搜索), which uses ultrasound-enhanced technology to localize lesions during biopsy procedures representing an estimated 1.3 million annual procedures in the United States.
The combined SCOUT (搜索) and OneMark platforms provide physicians with enhanced localization options during initial diagnostic biopsies, potentially reducing the need for separate tumor marking procedures before surgery.
Merit Medical Systems (搜索) announced on April 1, 2026, that it has acquired View Point Medical (搜索), Inc. for approximately $140 million, significantly expanding its therapeutic oncology portfolio dedicated to breast and soft tissue tumor localization. The acquisition makes View Point, a Carlsbad, California-based manufacturer of the OneMark Detection Imaging System (搜索) and OneMark Tissue Markers, a wholly-owned subsidiary of Merit.
Strategic Expansion in Breast Cancer Diagnostics
The acquisition strengthens Merit's position in wire-free, non-radioactive breast localization procedures, building upon its existing SCOUT (搜索) platform that utilizes radar technology for precision and accuracy. According to Martha G. Aronson, Merit's President and Chief Executive Officer, "View Point's unique ultrasound-enhanced technology offers a highly innovative solution to localize more lesions at the time of biopsy – representing an estimated 1.3 million procedures annually in the United States alone."
The OneMark System has received FDA clearance for its intended use and consists of a surgical detection console and ultrasound-enhanced tissue markers. The tissue markers are designed to be visible across commonly used imaging modalities while minimizing interference with imaging studies. When combined with Merit's SCOUT (搜索) platform, the integrated solution provides physicians with enhanced localization options during initial diagnostic biopsies.
Clinical Impact and Workflow Optimization
Adam Smith, Merit's Chief Commercial Officer, emphasized the clinical significance of the acquisition: "As treatment protocols evolve, the suspicious area is often most visible at the time of biopsy. Localizing these areas early in a patient's cancer journey can help physicians plan treatment and may help reduce the need for additional localization procedures."
The combined SCOUT (搜索) and OneMark platforms may reduce the need for separate procedures to mark tumor locations prior to surgery, potentially streamlining the diagnostic and treatment workflow for breast cancer (搜索) patients.
Financial Projections and Growth Outlook
The acquisition is structured with $90 million paid in cash at closing and two deferred payments of $25 million each scheduled for the first and second anniversaries of the closing date. For the remainder of 2026, the acquisition is projected to contribute revenue between $2 million and $4 million while diluting Merit's non-GAAP earnings per share by approximately $0.05.
Looking ahead to 2027, View Point is expected to generate revenue in the range of $14 million to $16 million and become accretive to non-GAAP earnings per share. Sales of the OneMark System are projected to grow at least 20% annually with 70% non-GAAP gross margins and accretive impact on non-GAAP operating margins.
Transaction Details and Integration
The transaction consideration of approximately $140 million includes the assumption of View Point liabilities. Piper Sandler & Co. served as financial advisor to Merit, while Baker & McKenzie LLP provided legal counsel for the transaction.
Merit Medical, founded in 1987, develops, manufactures, and distributes proprietary medical devices for interventional, diagnostic, and therapeutic procedures across cardiology, radiology, oncology, critical care, and endoscopy. The company employs approximately 7,600 people worldwide and serves customers through a global sales force and clinical support team of more than 800 individuals.